Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Long-term Efficacy of the Sphingosine 1-Phosphate Receptor Modulator Ozanimod by Age Category in Patients with Relapsing Multiple Sclerosis: Final Results from Two Phase 3 Trials and an Open-label Extension Trial

Author:Steinman, Lawrence   Selmaj, Krzysztof   Comi, Giancarlo   Bar-Or, Amit   Arnold, Douglas   Hartung, Hans-Peter   Montalban, Xavier   Havrdova, Eva   Sheffield, James   Cheng, Chun-Yen   Reardon, Jennifer   Riolo, Jon   Deboer, Erik   Kappos, Ludwig   Cohen, Jeffrey   Cree, Bruce   

Session Name:P2: Multiple Sclerosis: Clinical Practice and Decision Making 2  

Topic:Multiple Sclerosis  

Program Number:P2.007  

Author Institution:Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California, Stanford, CA  Center for Neurology, Lódz, Poland, and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland, Lodz, Poland  Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy, Milan, Italy  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA  NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, Quebec, Canada, Montreal, QC, Canada  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Australia  Department of Neurology, Medical University of Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Dusseldorf, Germany  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic, Prague, Czech Republic  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA